Boothbay Fund Management’s Centessa Pharmaceuticals CNTA Stock Holding History

Boothbay Fund Management’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-39,656	Closed	-$1.58M	–	2299
2026 Q1	$1.58M	Buy	39,656 +7,148	+22%	+$183K	0.02%	727
2025 Q4	$813K	Buy	32,508 +11,189	+52%	+$283K	0.01%	889
2025 Q3	$517K	Sell	21,319 -20,581	-49%	-$366K	0.01%	1146
2025 Q2	$551K	Hold	41,900	–	–	0.01%	875
2025 Q1	$603K	Hold	41,900	–	–	0.02%	794
2024 Q4	$702K	Buy	+41,900	New	+$694K	0.02%	755

Boothbay Fund Management's CNTA Position: Q2 2026 in Review

Boothbay Fund Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 39,656 shares — an estimated $1.58M sold.

Boothbay Fund Management first reported a position in CNTA in Q4 2024 and held it in 6 quarters. The position peaked at $1.58M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Boothbay Fund Management reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Boothbay Fund Management sold 39,656 Centessa Pharmaceuticals shares in Q2 2026, an estimated $1.58M.
Boothbay Fund Management first reported a position in Centessa Pharmaceuticals in Q4 2024 and held it in 6 quarters.
Boothbay Fund Management's Centessa Pharmaceuticals position peaked at $1.58M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.